Dicot's business concept is to develop the product Libiguin® as a drug for treating sexual dysfunctions. The development takes place on its own up to clinical phases.

Investor relations

Dicot rapporterar positiva studieresultat för Libiguin

Press release
13 October, 2020

Last day of trading with the warrants of series TO1 2019

Today, October 13, is the last day of trading with the warrants of series TO1 2019. The subscription period for the warrants of series TO1 2019 will continue up until October 15, 2020. Each warrant entitles the owner to subscribe for one point eighty...

Press release
12 October, 2020

Continued studies with Pelvipharm to generate knowledge about treatment times, doses and Libiguin's® mechanism of action

Press release: Uppsala, October 12, 2020. As previously reported, Dicot has conducted the first study in collaboration with Pelvipharm SAS with tests in a model for erectile function in normal rats. Satisfactory results showed that treatment with Dic...

Watch CEO Göran Beijer presenting the company:

Contact us

Dicot AB
Dag Hammarskjölds Väg 30
SE-752 37 Uppsala SWEDEN
+46 (0) 70-663 60 09
info@dicot.se

The information is processed according to our privacy policy.